Orange Book product · Brand (NDA)
COMETRIQ
CABOZANTINIB S-MALATE
At a glance
Nov 29, 2012
Approved
Brand (NDA)
Application
Not listed
TE code
8
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Nov 29, 2012
13 yr 9 mo ago
Today
Patent 7579473 expires
Listed drug substance patent expiration.
Aug 14, 2026
in 2 mo
Patent 11091439 expires
Listed drug substance patent expiration.
Jan 15, 2030
in 3 yr 8 mo
Patent 11091440 expires
Listed drug product patent expiration.
Jan 15, 2030
in 3 yr 8 mo
Patent 11098015 expires
Listed method-of-use patent (U-1617) expiration.
Jan 15, 2030
in 3 yr 8 mo
Patent 8877776 expires
Listed drug substance patent expiration.
Oct 08, 2030
in 4 yr 4 mo
Patent 11298349 expires
Listed drug product patent expiration.
Feb 10, 2032
in 5 yr 9 mo
Patent 12128039 expires
Listed drug product patent expiration.
Feb 10, 2032
in 5 yr 9 mo
Patent 9717720 expires
Listed drug product patent expiration.
Feb 10, 2032
in 5 yr 9 mo
Pharmaceutical detail
Active ingredient
CABOZANTINIB S-MALATE
Strength
EQ 80MG BASE
Dosage form
CAPSULE
Route
ORAL
TE code
Not listed
Application
NDA 203756
Product number
002
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Listed patents (8)
| Patent | Expires | In | Type |
|---|---|---|---|
| 7579473 | Aug 14, 2026 | in 2 mo | SubstanceProduct |
| 11091439 | Jan 15, 2030 | in 3 yr 8 mo | Substance |
| 11091440 | Jan 15, 2030 | in 3 yr 8 mo | Product |
| 11098015 | Jan 15, 2030 | in 3 yr 8 mo | U-1617 |
| 8877776 | Oct 08, 2030 | in 4 yr 4 mo | SubstanceProductU-1617 |
| 11298349 | Feb 10, 2032 | in 5 yr 9 mo | Product |
| 12128039 | Feb 10, 2032 | in 5 yr 9 mo | ProductU-1617 |
| 9717720 | Feb 10, 2032 | in 5 yr 9 mo | Product |
